Valuation : Replimune Group, Inc.

Market Cap 1.42B 1.22B 1.15B 1.05B 1.95B 134B 1.96B 13.58B 5.25B 68.67B 5.32B 5.21B 219B P/E 2027 *
-5.2x
P/E 2028 * -6.26x
Enterprise Value 1.32B 1.13B 1.06B 972M 1.81B 125B 1.82B 12.62B 4.88B 63.8B 4.94B 4.84B 203B EV / Sales 2027 *
30.8x
EV / Sales 2028 * 7.11x
Free-Float
98.35%
Yield 2027 *
-
Yield 2028 * -
1 day-1.80%
1 week-5.74%
Current month-3.46%
1 month+8.05%
3 months+64.66%
6 months+71.15%
Current year+51.95%
1 week 14.61
Extreme 14.61
16.33
1 month 12.27
Extreme 12.27
16.33
Current year 1.5
Extreme 1.5
16.33
1 year 1.5
Extreme 1.5
16.33
3 years 1.5
Extreme 1.5
20.05
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Director/Board Member 64 01/04/2020
Director/Board Member 61 01/10/2017
Chairman 54 01/04/2024
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 A Don

Founder

-50,000 0.0641%
8/17/26 A Sell

Chief Financial Officer

-9,256 0.0119%
8/11/26 A
Baker Bros. Advisors LP
BuyCompany 2,736,340 3.5056%
Change 5-day change 1-year change 3-year change Capi.($)
-1.80%-5.74%+144.54%-25.06% 1.42B
-0.82%-3.57%-3.71%+12.92% 48.41B
-1.29%-1.22%+404.92%+545.45% 45.01B
-3.20%+0.33%+38.11%+21.39% 44.07B
-1.89%-2.00%+1.45%+82.46% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.17%+3.78% - - 17.77B
-0.07%+1.32%+20.08%+117.95% 16.5B
-0.56%-1.85%+11.53%+30.40% 14.45B
-2.68%-0.56%+73.31%+40.56% 13.77B
Average -1.47%-0.12%+78.22%+96.61% 27.54B
Weighted average by Cap. -1.61%-0.14%+85.24%+131.34%

Financials

2027 *2028 *
Net sales 42.8M 36.8M 34.62M 31.59M 58.96M 4.06B 59.27M 410M 159M 2.07B 161M 157M 6.6B 193M 166M 156M 143M 266M 18.31B 267M 1.85B 716M 9.36B 725M 710M 29.79B
Net income -301M -259M -243M -222M -414M -28.51B -416M -2.88B -1.12B -14.57B -1.13B -1.1B -46.37B -244M -210M -198M -180M -337M -23.17B -338M -2.34B -906M -11.84B -918M -898M -37.68B
Net Debt -100M -86.37M -81.25M -74.15M -138M -9.52B -139M -963M -372M -4.87B -377M -369M -15.49B -44.05M -37.88M -35.63M -32.52M -60.69M -4.18B -61M -422M -163M -2.13B -165M -162M -6.79B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
08/09/26 $14.77 -1.80% 1,492,788
04/09/26 $15.04 -1.64% 910,229
03/09/26 $15.29 -4.32% 1,353,767
02/09/26 $15.98 +1.98% 1,989,600
01/09/26 $15.67 +2.42% 1,778,983
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.04USD
Average target price
19.50USD
Spread / Average Target
+29.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!